

COPY OF PAPERS ORIGINALLY FILED

Patent 270/070US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:) Group Art Unit: 1645
Langenfeld, John) Examiner: Not Yet Assigned
Serial No.: 10/044,716	BECEIVE
Filed: January 11, 2002) AUG 1 4 2002
For: BONE MORPHOGENETIC PROTEIN-2 IN THE TREATMENT AND DIAGNOSIS OF CANCER	Examiner: Not Yet Assigned RECEIVED AUG 1 4 2002 AUG 1 4 2002 TECH CENTER 1600/2900
SUPPLEMENTAL INFORMATIO	N DISCLOSURE STATEMENT
Commissioner for Patents Washington, D.C. 20231	
Dear Sir:	
In accordance with 37 CFR §§ 1.97 and 1.98, to Statement ("IDS") are brought to the attention of the CPTO-1449 and copies are enclosed for the convenience	
The items identified in this IDS may or may not submission thereof by Applicant is not to be construed or other information referred to therein is material or ceven qualifies as "prior art" under 35 USC § 102 with designated by Applicant as such.	onsidered to be material (37 CFR § 1.97(h)), or
Information Disclosure Sta	TEMENT FILING PROVISION:
This IDS is believed to be timely in that it is be within three months of the filing date of the application	eing submitted under 37 CFR § 1.97(b), that is (1) n, which is not a continued prosecution application
LA-240675.1	
CERTIFICATE O (37 C.F.R.	
I hereby certify that this paper (along with any referred to as being attached or date shown below with sufficient postage as First Class Mail in an envelope ad	, .
	Rachel Marquez Name of Person Mailing Paper
August 6, 2002 Date of Deposit	Signature of Person Mailing Paper

COPY OF PAPERS ORIGINALLY FILED

Patent 270/070US

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable.

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. 12-2475.

Dated: 3/6/02

LYON & LYON LLP

Sandra S./Fujiyama/

Reg. No. 46,713

22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP

633 W. Fifth Street, Suite 4700

Los Angeles, CA 90071

Phone: (213) 489-1600

Fax: (213) 955-0440

FORM PTO-1449	ATTY. DOCKET NO. 272/070US	SERIAL NO. 10/044,716	
CLIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Langenfeld, John		
AUG 1 2 2002 (Use several sheets if necessary)	FILING DATE: January 11, 2002	GROUP: 1645	
E TANDEMARK OF D.			

			U.S. PA	TENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC			COPY OF PAPERS ORIGINALLY FILED		CE	NED
	AD			ONIGHALLITIELD		RECE	3005
	AE					AUG 1	MEH 1800155 4 5005 NED
	AF					- ~ CE	MIER TOUS
	AG					TEURIS	
	AH						

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS	NO
	Al							
	AJ							<u></u>
	AK							

N	ON PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
 AL	Ikeda et al., "Cloning of Rat Type I Receptor cDNA for Bone Morphogenetic Protein-2 and Bone Morphogenetic Protein-4, and the Localization Compared With That of the Ligands," Developmental Dynamics, Vol. 206, (1996) pp. 318-329
 AM	ten Dijke et al., "Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity," Oncogene, Vol. 8, (1993) pp. 2879-1887
AN	
AO	

LA-242662.1	
EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant
Information Disclosure Statement – Section 9 PTO-1449